Abl Cytosolic Substrate
CAS No. 168202-46-8
Abl Cytosolic Substrate( —— )
Catalog No. M30182 CAS No. 168202-46-8
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbl Cytosolic Substrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
-
DescriptionAbl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number168202-46-8
-
Formula Weight1336.58
-
Molecular FormulaC64H101N15O16
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Glu}{Ala}{Ile}{Tyr}{Ala}{Ala}{Pro}{Phe}{Ala}{Lys}{Lys}{Lys}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Buchdunger E, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996 Jan 1;56(1):100-4.
molnova catalog
related products
-
AKE-72
AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.
-
Ponatinib
Ponatinib (AP 24534) is a potent, orally active pan-inhibitor of BCR-ABL kinase with IC50 of 0.37 and 2.0 nM for ABL and mutant ABLT315I, respectively.
-
DCC-2036
DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4 nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively.
Cart
sales@molnova.com